PZRXQ (PhaseRx) LT-Debt-to-Total-Asset: 0.60 (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx LT-Debt-to-Total-Asset?

PhaseRx PZRXQ -99.00% LT-Debt-to-Total-Asset is 0.60 as of Sep. 2017.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PhaseRx's long-term debt to total assests ratio for the quarter that ended in Sep. 2017 was 0.60.

PhaseRx's long-term debt to total assets ratio increased from Sep. 2016 (0.29) to Sep. 2017 (0.60). It may suggest that PhaseRx is progressively becoming more dependent on debt to grow their business.

PhaseRx  (OTCPK:PZRXQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PhaseRx LT-Debt-to-Total-Asset Related Terms

PhaseRx LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for PhaseRx's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx LT-Debt-to-Total-Asset Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
0.00 0.00 0.31

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.31 0.36 0.45 0.60

PhaseRx LT-Debt-to-Total-Asset Calculation

PhaseRx's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=5.127/16.448
=

PhaseRx's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2017 is calculated as

LT Debt to Total Assets (Q: Sep. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2017 )/Total Assets (Q: Sep. 2017 )
=3.611/6.038
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.60 mean?
PhaseRx (PZRXQ) has a LT-Debt-to-Total-Asset of 0.60 as of Sep. 2017. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PhaseRx and its competitors.
Is PhaseRx's LT-Debt-to-Total-Asset too high?
PhaseRx's current LT-Debt-to-Total-Asset is 0.60.
How does PhaseRx's LT-Debt-to-Total-Asset compare to NSPX and HSTC?
PhaseRx's LT-Debt-to-Total-Asset of 0.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PhaseRx and its competitors. PhaseRx's current LT-Debt-to-Total-Asset is 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current LT-Debt-to-Total-Asset of 0.60. The current LT-Debt-to-Total-Asset is 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current LT-Debt-to-Total-Asset is 0.60 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.